KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Subscribe To Our Newsletter & Stay Updated
